8-K current report · filed Aug 12, 2026

Arbutus Biopharma Corp (ABUS) 8-K Current Report: August 12, 2026

Item 2.02Item EX-99.1ABUS overview

Short answer

Arbutus Biopharma Corp (ABUS) filed an 8-K current report with the SEC on August 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial results for quarter ended June 30, 2026.

Arbutus Biopharma Corp 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q2 2026 financial results for quarter ended June 30, 2026
  • Press release issued August 12, 2026
  • Exhibit 99.1 contains financial results and additional company information

Item EX-99.1 · Exhibit EX-99.1

  • Q2 revenue $1.0M versus $10.7M, reflecting the absence of a prior-year $9.6M deferred-revenue recognition
  • Moderna settlement delivered $178.4M in July, materially strengthening liquidity beyond June 30 cash and securities of $92.6M
  • Planned shareholder capital return of up to approximately $230M beginning Q3 2026, subject to board approval
  • Pfizer and BioNTech patent lawsuits span 21 countries, creating potential litigation-driven licensing or damages upside
  • FDA alignment on imdusiran Phase 2b design reduces regulatory uncertainty, but clinical execution and funding remain key risks

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Arbutus Biopharma Corp 8-K filings

Get the next ABUS 8-K as it lands

Follow ABUS for push alerts, or ask the research agent what this filing means.